(8E,12E,14E)-7-(N-(2-(N',N'-diethylamino)ethyl)-N-methyl-carbamoyloxy)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (8E,12E,14E)-7-(N-(2-(N',N'-diethylamino)ethyl)-N-methyl-carbamoyloxy)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide
• 英文别名: [(4E)-10-hydroxy-2-[(2E,4E)-6-hydroxy-7-[3-(3-hydroxypentan-2-yl)oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] N-[2-(diethylamino)ethyl]-N-methylcarbamate
• 化学式: C₃₆H₆₂N₂O₈
• 分子量: 650.897
• InChiKey: VQQUTBSDPUPBAA-WNXJUDQWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  46
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• Novel physiologically active substances
  申请人：Kotake Yoshihiko

  公开号：US20050245514A1

  公开（公告）日：2005-11-03

  Compounds represented by the following general formula (I), pharmacologically acceptable salts thereof or hydrates of the same: (I) wherein W represents and R 3 , R 7 , R 16 , R 17 , R 20 , R 21 and R 21′ are the same or different and each represents hydrogen, etc. Because of inhibiting angiogenesis and inhibiting the production of VEGF particularly in hypoxia, the compounds (I) are useful as remedies for solid cancer.

  具有下述通式(I)表示的化合物、其药理学上可接受的盐或水合物：(I)其中W代表，R3、R7、R16、R17、R20、R21及R21'相同或不同，各自代表氢等。由于能抑制血管生成及在缺氧条件下抑制VEGF的产生，化合物(I)可作为实体癌症的治疗药物。
• NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES
  申请人：MERCIAN CORPORATION

  公开号：EP1548121A1

  公开（公告）日：2005-06-29

  Compounds represented by the following general formula (I), pharmacologically acceptable salts thereof or hydrates of the same: (I) wherein W represents and R3, R7, R16, R17, R20, R21 and R21' are the same or different and each represents hydrogen, etc. Because of inhibiting angiogenesis and inhibiting the production of VEGF particularly in hypoxia, the compounds (I) are useful as remedies for solid cancer.

  由以下通式（I）代表的化合物、其药理学上可接受的盐或其水合物： (I) 其中 W 代表 和 R3、R7、R16、R17、R20、R21 和 R21'相同或不同，且各自代表氢等。由于抑制血管生成和抑制血管内皮生长因子的产生，特别是在缺氧的情况下，化合物（I）可作为治疗实体癌的药物。
• Physiologically active substances
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1548121B1

  公开（公告）日：2015-04-29
• US7256178B2
  申请人：——

  公开号：US7256178B2

  公开（公告）日：2007-08-14